The expression pattern of ROR1 has made it a preferred target for the development of specific anti-cancer therapeutics including monoclonal antibodies (cirmtuzumab [69]), CAR-T cells [70] or small molecule inhibitors [71,72,73,74] which block the phosphoinositide 3-kinase (PI3K)/AKT axis and exert similar biological effects as PI3K/AKT inhibitors [75]. The gene discussed is AKT1; the disease is cancer.